Zhejiang Shapuaisi Pharmaceutical (603168.SH) obtained the drug registration certificate for sodium bromfenac eye drops.
SAPAS (603168.SH) announcement, recently, the company has received approval from the National Medical Products Administration to issue bromfenac...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that recently, the company received the "Drug Registration Certificate" for the sodium bromfenac eye drops issued by the National Medical Products Administration. The sodium bromfenac eye drops approved this time are used for symptomatic treatment of inflammatory diseases of the external and anterior parts of the eye: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.
Related Articles
"Citigroup gives Biohaven (BHVN.US) a 'buy' rating, bullish on the potential of its core drug rimegepant receiving FDA approval."
HK Stock Market Move | ASMPT(00522) rose by more than 5%, and its wholly-owned subsidiary will become a key shareholder of Shenzhen Original Advanced Compounds, effectively promoting international cooperation in the semiconductor industry.
It is a good opportunity to enter! JP Morgan: Adobe (ADBE.US) valuation is low, AI and price increases together build a growth moat.
"Citigroup gives Biohaven (BHVN.US) a 'buy' rating, bullish on the potential of its core drug rimegepant receiving FDA approval."
HK Stock Market Move | ASMPT(00522) rose by more than 5%, and its wholly-owned subsidiary will become a key shareholder of Shenzhen Original Advanced Compounds, effectively promoting international cooperation in the semiconductor industry.
It is a good opportunity to enter! JP Morgan: Adobe (ADBE.US) valuation is low, AI and price increases together build a growth moat.
